ISV - Sector: Healthcare --- Industry: Biotechnology & Drugs

[setravis]

Recent Company Developments

On November 30, 2005 InSite Vision reported top line results from the first of two phase 3 clinical trials of AzaSite eye drops. AzaSite is a sterile, topical ophthalmic anti-infective solution containing 1.0% azithromycin formulated in DuraSite(R) (InSite Vision's patented drug delivery system). The multicenter study was randomized, double masked, and active-controlled. In this trial, designed to show comparability with the marketed eye drop, tobramycin, with respect to the resolution of bacterial conjunctivitis, AzaSite demonstrated a clinical resolution rate of 80% as compared to 78% for tobramycin.

In December 2005 and January 2006, InSite Vision announced that debt financing had been secured, which would allow data generation and preparation of its NDA planned to be submitted to the FDA. In closings held in December 2005 and January 2006, InSite Vision raised an aggregate of $6.3 million before expenses through the issuance of Senior Secured Notes and the issuance of warrants to purchase 1,260,000 shares of Common Stock at an exercise price of $0.82 per share. InSite Vision also issued a warrant to purchase 200,000 shares of Common Stock to the placement agent in the transaction.

On January 13, 2006, InSite Vision announced the completion of enrollment of the second phase 3 clinical trial for AzaSite. The trial was a randomized, double masked, multicenter study that included patients from 1 - 96 years of age. The goal of the second study was to demonstrate superiority of AzaSite as compared to a vehicle (a placebo that does not contain any active drug substance) in the clinical resolution of the bacterial conjunctivitis. Clinical resolution was the primary efficacy endpoint. A secondary endpoint was bacterial eradication. On March 14, 2006, top line results were reported from this second clinical trial. Patients treated with AzaSite had a significantly higher clinical resolution rate, the trial's primary efficacy end point and a significantly higher bacterial eradication rate, a secondary end point, than those receiving the vehicle.

On February 22, 2006 InSite Vision reported that two abstracts were accepted for presentation at the upcoming meeting of the Association for Research in Vision and Ophthalmology at the Fort Lauderdale Convention Center in Ft. Lauderdale, Florida, to be held April 30 - May 4, 2006. The presentations will describe the results of the AzaSite vs. tobramycin clinical trial.

[stockontop]

INSITE VISION INC Files SEC form 10-K, Annual Report
http://biz.yahoo.com/e/060331/isv10-k.html

[setravis]

Repeat myself......

With this chart it is a stock worth holding onto with only a trailing stop.
This stock is poised for much higher prices over the coming months after a
consolidation period here.Stochastic bouncing up out of oversold area,buy zone.

Going in and out of stocks is not a strategy that will generate the great profits you really want. Finding a winner and sticking with it until it hits a trailing stop is the way to Real earnings.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Technicals
Record Price High
Close Above the 13-day EMA
Most Actives
Percentage Gainer

Last Price Quote is:
10.98%above 13-day EMA
32.40%above 50-day EMA
RS Rating: 99 

[setravis]

Press Release Source: Rodman & Renshaw, LLC


Rodman & Renshaw, LLC Announces Investment Opinion on InSite Vision, Inc. with a Market Outperform Rating
Friday March 31, 2:56 pm ET 
Analyst Sets 12 Month Target Price of $4


NEW YORK--(BUSINESS WIRE)--March 31, 2006--Rodman & Renshaw, LLC initiated research coverage of InSite Vision, Inc. (AMEX: ISV - News) with a Market Outperform Rating and a 12-month price target $4. Ilya Kravets, Senior Specialty Pharmaceuticals Analyst, issued the report.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a privately held, full-service investment bank committed to fostering the long-term success of growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. More information is available at www.rodmanandrenshaw.com

None of the research analysts or the research analyst's household has a financial interest in the securities of InSite Vision, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of February 28, 2006, neither Rodman & Renshaw, LLC nor its affiliates beneficially own 1% or more of any class of common equity securities of InSite Vision, Inc.

Neither the research analyst nor Rodman & Renshaw, LLC has any material conflict of interest with InSite Vision, Inc., of which the research analyst knows or has reason to know at the time of publication of this research report.

Rodman & Renshaw, LLC or its affiliates did not receive compensation from InSite Vision, Inc. for investment banking services within the last twelve months and Rodman & Renshaw, LLC intends to seek compensation from InSite Vision, Inc. for investment banking services within three months, following publication of the research report.

Neither the research analyst nor any member of the research analyst's household nor Rodman & Renshaw, LLC serves as an officer, director or advisory board member of InSite Vision, Inc.

Rodman & Renshaw, LLC does not make a market in InSite Vision, Inc.' securities as of the date of this research report.

The above information is not intended to be used as a primary basis of investment decisions. It is not a representation by Rodman & Renshaw, LLC or an offer or the solicitation of an offer to buy any security. Before investing in InSite Vision, Inc., you should carefully consider your risk tolerance and financial objectives.

Contact:
Rodman & Renshaw, LLC
William A. Iommi, 212-356-0549
Fax: 212-581-5690

--------------------------------------------------------------------------------
Source: Rodman & Renshaw, LLC

[setravis]

Outstanding......

Volume: 1,714,000
Avg Vol (3m): 843,818

Technicals
Record Price High
Close Above the 13-day EMA
Most Actives
Percentage Gainer

Last Price Quote is:
15.59%above 13-day EMA
37.89%above 50-day EMA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

keeps a moving.....

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
17.57%above 13-day EMA
41.28%above 50-day EMA
RS Rating: 99 

Fundamentals
Coverage Initiated: Mkt Outperform

Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

• Coverage initiated on Insite Vision by Rodman & Renshaw
Briefing.com (Tue 2:06pm) 

[setravis]

Legs to stand on....
Great chart

Technicals
Percentage Gainer

Last Price Quote is:
10.26%above 13-day EMA
34.91%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

[setravis]

A dip ...headed back up.

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
3.85%above 13-day EMA
22.54%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

[setravis]

Awesome chart.......

Technicals
Record Price High

Last Price Quote is:
8.37%above 13-day EMA
27.92%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

[beroznikmal]

I first bought isv on 3/13/06 just before the breakout. and held thru the conference call day... yes the day that the stock dipped within seconds of the opeing bell but ramped up almost immediately. I did a search a few days ago and did not find this post, hum ... interesting... Travis, what is your take on this stock...


Thanks
B

[beroznikmal]

ISV made an interesting move today.. formed a hammer.... from its past performance, ISV usually tend to shakeout before it setitself to move up.....
not too late to get in ....
cheers
B

[setravis]

Look for new 52 week high in ISV next week.

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
8.76%above 13-day EMA
18.31%above 50-day EMA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

[beroznikmal]

Still holding strong:P

[beroznikmal]

isv has been behaving very welll.... despite all the down acion...

[setravis]

For every financial reason you should invest in this company.
There is insider buying and the stock is increasing in value !
Pretty good relative strength.

Technicals
Last Price Quote is:
0.25%above 13-day EMA
8.87%above 50-day EMA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform